Aclarion, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Lucas Ward from Ascendiant maintained a Buy rating on the stock and has a $23.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lucas Ward’s rating is based on several positive developments at Aclarion, Inc. The company has shown significant revenue growth, driven by an increase in Nociscan report volumes, particularly due to favorable insurance coverage in the UK. This growth is supported by strategic investments in clinical trials and marketing efforts, which are expected to further enhance the company’s market presence.
Additionally, Aclarion’s addressable market is substantial, with a large number of potential patients suffering from lower back pain and degenerative spine disease. The company’s financial position is also strong, with sufficient cash reserves to support operations for the next six quarters. Furthermore, the recent increase in the 12-month price target reflects confidence in the company’s commercialization efforts and potential for stock price appreciation.
Ward covers the Healthcare sector, focusing on stocks such as Aclarion, Inc., Heart Test Laboratories, Inc., and Vivos Therapeutics. According to TipRanks, Ward has an average return of -50.2% and a 15.22% success rate on recommended stocks.